ClinicalTrials.gg
RecruitingNCT06214520EmpowerPlusUpdated Nov 14, 2024

App-based Motivational Interviewing and Artificial Intelligence in Diabetes Management

An interventional study of App-based Motivational Interviewing & Human health coaching and Empower+ App & Smartwatch wearable tracker in Diabetes Mellitus Type 2, sponsored by Singapore General Hospital. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
21 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital — 5 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Singapore General Hospital.

Planned enrollment
2nd of 13
525 · median 150
Started
2024
with 1 other
No phase
13 of 15
5 open now
Registered
13th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 13 with no phase, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, or all of them as a file.
02

Study summary

There is an urgent need for better control and prevention of complications in type 2 diabetes mellitus (T2DM). Behavioural change is critical, and while literature suggests that motivational interviewing (MI) may be effective in improving glycemic control, none has explored app-based MI designed specifically for T2DM. The overall objective of this project is to determine the effectiveness of primary care model combining app-based MI and AI-powered personalised nudges delivered through a mobile application (app) for diabetes management (EMPOWER-PLUS). The project aims to evaluate the effectiveness and implementation of MI and nudges through EMPOWERPLUS to deliver diabetes management through a randomised controlled trial (RCT). This will be a 3-arm RCT with primary outcome measure being the difference in HbA1c level at week 36 between the intervention and control arms. Secondary outcome measures include cost-effectiveness, quality of life, medication adherence, diet, and physical activity. Eligible poorly controlled T2DM patients with T2DM in polyclinics will be randomized to intervention arm who will receive EMPOWER-PLUS and smartwatch wearable on top of their usual clinical care. The first control group will have access to nudges delivered through app and smartwatch wearable in addition to usual clinical care but will not receive MI. The second control group will receive usual care (no access to MI, nudges and smartwatch wearable). This study is important to improve T2DM outcomes and reduce healthcare utilization by providing scientifically evaluated and transformative primary care model. Leveraging on digital technology and artificial intelligence to drive personalised care, behavioural change and empowerment has huge potential for scale up.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 21 years and above
  • Have been diagnosed with diabetes (T2DM)
  • Had result of ≥ 7.5% within past 3 months
  • Physically able to exercise
  • Able to read and converse in English
  • Able to download the Empower+ app, use the smartphone wearable tracker, and conform to the minimum smartwatch and app monitoring schedule

Exclusion criteria

Exclusion Criteria:

  • On bolus insulin treatment
  • Require assistance with basic activities of daily living (BADL)
  • Have planned major operation or surgical procedure within 9 months from the time of recruitment
  • Cognitively impaired (scored \< 6 on the Abbreviated Mental Test)
  • Currently pregnant or lactating
  • Current participants of ongoing clinical trials involving the usage of a smartphone wearable tracker or mobile health app to assist diabetes management
  • Past Empower study participants who refused to participate in future Empower studies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
525 participants (estimated)

Study arms

  • Experimental
    Intervention

    Intervention Group

    Behavioral: App-based Motivational Interviewing & Human health coaching · Behavioral: Empower+ App & Smartwatch wearable tracker

  • Active comparator
    Control 1

    Control group 1

    Behavioral: Empower+ App & Smartwatch wearable tracker

  • No intervention
    Control 2

    Control group 2

Interventions

  • BehavioralApp-based Motivational Interviewing & Human health coaching

    Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking. App-based Motivational Interviewing \& Human health coaching: The health coach will conduct 1:1 or group-based health coaching as appropriate virtually over the EMPOWER+ app, videoconferencing platform or telephone call.

  • BehavioralEmpower+ App & Smartwatch wearable tracker

    Patients in the intervention arm will be given a smartwatch wearable device and will be encouraged to wear it for at least 10 hours per day. Patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the EMPOWER+ app for real-time tracking.

06

What researchers measure

Primary outcomes

  1. HbA1c

    Difference between HbA1c measured at the in-house laboratory at polyclinics, at baseline and the 9-month mark.

    Time frame: 9 months

Secondary outcomes

  1. HbA1c

    Difference between HbA1c measured at the in-house laboratory at polyclinics, at baseline and the 6-month mark. HbA1c will be also retrieved from the Electronic Medical Record over the follow-up period (from month 10 to 18, if any).

    Time frame: 18 months

  2. Patient activation score

    Measured by patient activation measure (PAM), at baseline and the 9-month mark. For each item in PAM, the raw score ranges from 1 (Disagree strongly) to 4 (Agree strongly), and 0 is given to option "Not Applicable", with a higher score indicating a higher level of patient activation.

    Time frame: 9 months

  3. Physical activity - steps

    Measured by the smartphone wearable tracker over 9 months.

    Time frame: 9 months

  4. Physical activity - active minutes

    Measured by the smartphone wearable tracker over 9 months.

    Time frame: 9 months

  5. Sleep quality

    Measured by the smartphone wearable tracker over 9 months.

    Time frame: 9 months

  6. Sleep pattern

    Measured by the smartphone wearable tracker over 9 months.

    Time frame: 9 months

  7. Heart rate

    Measured by the smartphone wearable tracker over 9 months.

    Time frame: 9 months

  8. Medication adherence

    Measured by Voils, at baseline and the 9-month mark. For each item in Voils, the raw score ranges from 1 (missed medication none of the time) to 5 (missed medication every time), with a higher score indicating a poor level of medication adherence (or equivalently a higher level of medication non-adherence).

    Time frame: 9 months

  9. Dietary changes

    Measured with the Empower+ app (calorie intake, carbohydrate and sugar intake) over 9 months.

    Time frame: 9 months

  10. Health-related Quality of life

    Measured by EuroQol-5D-5L (EQ-5D-5L) combined with global health rating on a visual analogue scale (EQ-VAS) at baseline and the 9-month mark. Each dimension in the EQ-5D-5L has five response levels ranging from no problems (Level 1) to extreme problems (Level 5). There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health). For EQ-VAS, the raw score ranges from 0 to 100, with a higher score indicating a better health that the participant can imagine. The converted index value will be ranging from -0.5 to 1.0, where 0 is the value of a health state equivalent to death, negative values representing values as worse than dead, and 1 is the value of full health.

    Time frame: 9 months

  11. Direct healthcare cost

    Retrieved from the electronic medical records and recorded in survey form: Costs of consultations, lab tests, medications, admissions, at baseline and the 9-month mark.

    Time frame: 9 months

  12. Indirect healthcare cost

    Measured by survey, including self-reported income, travel cost, at baseline and the 9-month mark.

    Time frame: 9 months

  13. Indirect healthcare cost

    Measured by survey - Work Productivity and Activity Impairment (WPAI), at baseline and the 9-month mark. The WPAI-GH consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS). For the last two items, the raw scores range from 0 to 10, with a higher score indicating the patient being more affected by his/her health problems.

    Time frame: 9 months

  14. Usability of the Empower+ app and Motivational Interviewing module

    Measured by the System Usability Scale (SUS), at the 1-month mark (for intervention group and control group 1). For each item in SUS, the raw score ranges from 1 to 5, with a higher score for positive statements and a lower score for negative statements indicating a better usability.

    Time frame: 1 month

07

Study locations

3 of 3 sites recruiting
  • SingHealth Polyclinic (Punggol)
    Singapore, Singapore
    Recruiting
  • SingHealth Polyclinic (Sengkang)
    Singapore, Singapore
    Recruiting
  • SingHealth Polyclinic (Tampines)
    Singapore, Singapore
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Oct 2025, 20 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 19, 2024
StartActual
Feb 23, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Jun 30, 2026
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06214520
Collaborators
SingHealth Polyclinic - Sengkang, SingHealth Polyclinic - Punggol, SingHealth Polyclinic - Tampines, Tiong Bahru Community Health Centre
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Feb 23, 2024
Primary completion
Oct 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Nov 14, 2024

Study contacts

Lian Leng Low
Contact
low.lian.leng@singhealth.com.sg
63265872
Lian Leng Low
principal investigator · Singhealth Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion